近期的药物价格争论以及对于生物技术泡沫的担忧,都没有让部分精明的资产经理人灰心,他们依然确信,科技方面新近取得的成果将会引领下一个药物研究新纪元,并开发出以消费者为导向的、研究数据为基础的全新药品。在波士顿剧院区附近,到访者很容易会把交叉基金公司RA资本管理(RA Capital Management)的办公室错认成周边那些科技初创公司。炫目明亮的入口、可自由使用的站立式办公桌、储备充足的公共茶水间,所 Recent drug price controversy and fears of a biotech bubble have not discouraged some astute asset managers who are still convinced that the recent gains in technology will lead the next era of drug research and develop a new consumer- Oriented, research-based new medicines. Near Boston’s theater district, visitors can easily mistake the offices of RA Capital Management, a cross-fund firm, for technology start-ups nearby. Bright, dazzling entrance, free-standing standing desk, well-stocked communal pantries